Investor Relations

Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack applies its systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has six targeted therapeutic oncology candidates in clinical development.

View all »   RSSRecent Releases

Mar 26, 2015
Merrimack to Highlight Extensive Oncology Pipeline at the 2015 American Association for Cancer Research Annual Meeting

Feb 26, 2015
Merrimack Pharmaceuticals Reports Fourth Quarter 2014 Financial Results

Feb 19, 2015
Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Biomarker-Selected Clinical Trial of MM-121 in Patients with Heregulin Positive Non-Small Cell Lung Cancer

Feb 12, 2015
Merrimack Pharmaceuticals Announces Timing of Fourth Quarter 2014 Investor Conference Call

Stock Quote (NASDAQ: MACK)

Price:
11.61

Change:
+ 0.36

Day High:
11.75

Day Low:
11.26

Volume:
998,000

4:00 PM ET on Mar 27, 2015
Delayed ~20 min. By eSignal.

Shareholder Tools